Skip to content
Open access

FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study

Oct 2026 · Translational Oncology · Vol 74 · 0 citations · 36 references
Medicine

Abstract

Highlights • No significant OS or PFS differences were observed between regimens after matching.• Survival differences before matching may partly reflect patient selection.• ARID1A and RNF43 mutations were associated with shorter PFS with Gem/Nab-P.• Exploratory genomic associations require validation in larger prospective cohorts.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.